Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277524 · ClinicalTrials.gov registry record
OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.
A clinical trial, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Terminated
- Registry status
- 3,032
- Enrollment target
NCT00277524 is a clinical trial that was terminated before completion, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 3,032 participants.
The verdict
NCT00277524 was terminated before completion, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- TERMINATED
- Registry status
- 3,032 participants
- Enrollment target
Study Summary
The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe Implantable Cardioverter Defibrillator(ICD)therapy utilization for life threatening arrhythmias in primary and secondary prevention study participants. This study will assess therapies in Medtronic pacemaker, defibrillator, and cardiac resynchronization therapy devices. The first therapy is for reducing unnecessary pacing in pacemaker patients. The second therapy provides pacing therapy in an attempt to stop fast or life threatening ventricular arrhythmias in lieu of delivering a defibrillation shock. The third therapy is a diagnostic measurement of a patient's fluid status and provides the physician information on the patient's heart failure status. The study will also assess the time to a patient's first defibrillation shock and will verify that the shock was for a fast or life threatening ventricular rhythm.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,032 participants |
| Start Date | 2005-08 |
| Est. Completion | 2010-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00277524
The ClinicalTrials.gov registry entry for NCT00277524 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3,032 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00277524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00277524 about?
NCT00277524 is a clinical study titled "OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.". The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe Implantable Cardioverter Defibrillator(ICD)therapy utilization for life threatening arrhythmias in primary and secondary prevention study participant...
What is the current status of trial NCT00277524?
This trial is currently terminated. The enrollment target is 3,032 participants. The study started on 2005-08. Estimated completion is 2010-11.
Who is sponsoring clinical trial NCT00277524?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.